CD19-CART in the Treatment of R/R CD19 Positive Non-Hodgkin's Lymphoma

Non Hodgkin Lymphoma Clinical Trial

Official title:

Clinical Study on the Treatment of Relapsed or Refractory CD19 Positive Non-Hodgkin's Lymphoma Patients With Target CD19 Chimeric Antigen Receptor T Cell Infusion

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04237428
• Other study ID #: PG-CART-19-001
• Status: Recruiting
• Phase: N/A
• Start date: May 31, 2019
• Est. completion date: May 31, 2021

Study information

• Verified date: January 2020
• Source: PersonGen BioTherapeutics (Suzhou) Co., Ltd.
• Contact: Mingzhi Zhang, Doctor
• Phone: +8613838565629
• Email: mingzhi_zhang[@]126.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To evaluate the safety and efficacy of targeted CD19 chimeric antigen receptor T cell infusion in the treatment of relapsed or refractory CD19 positive non-Hodgkin's lymphoma.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 20
• Est. completion date: May 31, 2021
• Est. primary completion date: June 15, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Subjects with CD19 positive, relapsed or refractory diffuse large B cell lymphoma and follicular lymphoma who have no effective treatment (such as autologous or allogeneic stem cell transplantation) and have a survival time of several months or less than 2 years must meet all of the following inclusion criteria, and those who do not meet any of the exclusion criteria can be included:

1. Non Hodgkin's lymphoma was confirmed by histological examination, and one of the following conditions was met:

1. Relapsed and refractory CD19 positive diffuse large B-cell lymphoma: at least after the standard second-line drug treatment, the efficacy evaluation did not reach partial remission or above, or reached partial remission or disease progression after partial remission, or relapsed after complete remission;

2. Relapsed and refractory CD19 positive follicular lymphoma: at least after the standard three-line drug treatment, the efficacy evaluation did not reach partial remission or above, or reached partial remission and disease progress after partial remission, or relapsed after complete remission;

3. Relapsed refractory CD19 positive diffuse large B-cell lymphoma and follicular lymphoma: primary drug resistance; relapse within 1 year after autologous stem cell transplantation only, not affected by other treatment methods previously used; CD20 positive patients should receive corresponding targeted treatment;

2. Age: 18-65 years (including boundary value), gender unlimited;

3. The expected survival time was more than 3 months;

4. ECOG score 0-1 (dose increasing stage), ECoG score 0-2 (expanding group stage);

5. The functions of liver and kidney, heart and lung meet the following requirements:

? Creatinine = 1.5 ULN

?ALT/AST =2.5 ULN;

? Total bilirubin = 1.5 × ULN;

? Baseline oxygen saturation = 92%;

? No pericardial effusion was detected by echo;

6. According to Lugano's response standard, there should be at least one measurable tumor focus;

7. Be able to understand the test and have signed the informed consent.

Exclusion Criteria:

1. Before screening, they received other chimeric antigen receptor therapy or gene modified cell therapy;

2. Hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) is positive and the DNA titer of peripheral blood hepatitis B virus (HBV) is not within the normal reference range; hepatitis C virus (HCV) antibody is positive and peripheral blood HCV RNA is positive; human immunodeficiency virus (HIV) antibody is positive; cytomegalovirus (CMV) DNA is positive; syphilis is positive ;

3. Subjects who were undergoing systemic steroid therapy at the time of screening and who were determined by the investigator to require long-term systemic steroid therapy during the treatment (except for inhalation or local use);

4. In addition to cervical carcinoma in situ, basal cell or squamous cell skin cancer, local prostate cancer after radical operation, and breast ductal carcinoma in situ after radical operation, malignant tumors other than B-cell acute lymphoblastic leukemia in the first 5 years were screened;

5. Subjects with graft-versus-host disease (GVHD), autoimmune diseases (such as rheumatoid arthritis, systemic lupus erythematosus and Crohn's disease) and / or requiring immunosuppressant within 2 years;

6. Any unstable heart disease: including but not limited to unstable angina, myocardial infarction (within 6 months before screening), congestive heart failure (NYHA classification = grade III) and severe arrhythmia;

7. Any unstable systemic diseases: including but not limited to liver, kidney or metabolic diseases requiring drug treatment;

8. Subjects who received stem cell transplantation within 6 weeks after CD19 car-t infusion were planned;

9. Invasion of central nervous system;

10. Pregnant women and lactating women; and female subjects who plan pregnancy within 1 year after cell transfusion or male subjects whose partners plan pregnancy within 1 year after cell transfusion;

11. According to the judgment of the researchers, it does not conform to the situation of cell preparation;

12. Other researchers think it's not suitable for enrollment.

Related Conditions & MeSH terms

• Lymphoma
• Lymphoma, Non-Hodgkin
• Non Hodgkin Lymphoma

Intervention

Biological:
• CD19 CAR-T cells infusion
Biological: CD19 CAR-T cells infusion Biological: CD19 CAR-T cells infusion. Pretreatment: patients enrolled in this study will receive cyclophosphamide or fludarabine plus cyclophosphamide. CD19 CAR-T cells infusion are allowed within 2 weeks after treatment. CD19 CAR-T cells infusion: 30-60 minutes before infusion, H1 anti-histamine agents are applied (acetaminophen 30mg,po.; promethazine 25mg,i.v. ; diphenhydramine 0.5-1mg/kg, no more than 50mg.). Non-physiological doses of corticosteroids are not applied for patients during treatment or recovery unless a life-threatening emergency occurs. CD19 CAR-T cells are infused into patients for one time, the number of infused CD19 CAR-T cells are 0.5-4×10^6/kg.

Locations

Country	Name	City	State
China	First Affiliated Hospital of Zhengzhou University	Zhengzhou	Henan

Sponsors (2)

Lead Sponsor	Collaborator
PersonGen BioTherapeutics (Suzhou) Co., Ltd.	The First Affiliated Hospital of Zhengzhou University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	BORR	Best objective response rate	6 months
Secondary	Incidence of AE	Incidence of adverse reactions	2 years
Secondary	Pharmacokinetic parameters	the area under the curve of 28 days AUC0-28d and 90 days AUC0-90d of targeting CD19 chimeric antigen receptor T cells in peripheral blood after administration	90 Days
Secondary	Overall survival time	Overall survival time	through study completion, an average of 5 year
Secondary	Duration of remission after administration	Duration of remission after administration	through study completion, an average of 5 year
Secondary	Disease progression free survival	Disease progression free survival	through study completion, an average of 5 year